Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Real World Results of Brexucabtagene Autoleucel for Patients with Relapsed/Refractory Mantle Cell Lymphoma - First German/Swiss Analysis

Blood (2023) 142 (Supplement 1): 4394.

https://doi.org/10.1182/blood-2023-182415

Published: 2023

Journal Articles

Immune-Effector-Cell-Associated-Neurotoxicity-Syndrome (ICANS) Pathophysiology Is Mediated By Microglia TGF-β-Activated Kinase-1 Signaling

Janaki Manoja Vinnakota, Francesca Biavasco, Marius Schwabenland, Chintan Chhatbar, Rachael C Adams, Daniel Erny, Sandra Duquesne, Nadia El Khawanky, Henrike Salié, Dimitrios Athanassopoulos, Lukas Braun, Dominik Schmidt, Viktor Fetsch, Rebeka N. Javorniczky, Jenny N.H.G Ho, Reinhard Marks, Ralph Wäsch, Federico Simonetta, Geoffroy Andrieux, Dietmar Pfeifer, Gianni Monaco, Christian Capitini, Terry J. Fry, Thomas Blank, Bruce R Blazar, Eva-Maria Wagner Drouet, Matthias Theobald, Clemens Sommer, Matthias Stelljes, Christian Reicherts, Astrid Jeibmann, Jens Schittenhelm, Camelia-Maria Monoranu, Andreas Rosenwald, K. Martin Kortüm, Leo Rasche, Hermann Einsele, Philipp Tobias Meyer, Joachim Brumberg, Andreas Mackensen, Michael von Bergwelt-Baildon, Roland Coras, Nathalie L. Albert, Laura M. Bartos, Matthias Brendel, Adrien Holzgreve, Melanie Boerries, Crystal L. Mackall, Justus Duyster, Natalie Koehler, Felix Strübing, Bertram Bengsch, Marco Ruella, Marion Subklewe, Louisa von Baumgarten, Saar Gill, Marco Prinz, Robert Zeiser

Blood (2023) 142 (Supplement 1): 100.

https://doi.org/10.1182/blood-2023-184867

Published: 2023

Journal Articles

Implementation of CMV-T-Track® in Clinical Routine to Guide Management of CMV Reactivation

Jonas Wißkirchen, Diana Wolff, Isabelle Ries, Oliver Kriege, Pascal Wölfinger, Beate Hauptrock, Matthias Theobald, Eva-Maria Wagner Drouet

Blood (2023) 142 (Supplement 1): 2180.

https://doi.org/10.1182/blood-2023-187382

Published: 2023

Journal Articles

Comparison of Fludarabine/Melphalan (FluMel) with Fludarabine/Melphalan/BCNU or Thiotepa (FBM/FTM) in Patients with AML in First Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation - a Registry Study on Behalf of the EBMT Acute Leukemia Working Party

Blood (2022) 140 (Supplement 1): 2110–2112.

https://doi.org/10.1182/blood-2022-162277

Published: 2022

Journal Articles

Itacitinib and Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravitas-309

Annie Im, Daniel Wolff, Corey Cutler, Robert Zeiser, Nirav N. Shah, Ming Tony Tan, Jaime Sanz, Haris Ali, Giuseppe Milone, Arjun D. Law, Domenico Russo, Eva-Maria Wagner, Olga Ivanova, Kevin Hou, Maureen Bleam, Rodica Morariu-Zamfir, Steven Z Pavletic

Blood (2022) 140 (Supplement 1): 1870–1871.

https://doi.org/10.1182/blood-2022-169605

Published: 2022

Journal Articles

Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation

Blood (2022) 140 (Supplement 1): 2389–2391.

https://doi.org/10.1182/blood-2022-157890

Published: 2022

Journal Articles

In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial

Blood (2022) 140 (Supplement 1): 9–11.

https://doi.org/10.1182/blood-2022-159962

Published: 2022

Journal Articles

Induction of a Systemic Immune Response during Use of an Allogenic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML Patients Correlates with Clinical Response and MRD Conversion

Arjan A. Van de Loosdrecht, Jacqueline Cloos, Eva-Maria Wagner-Drouet, Uwe Platzbecker, Tobias A.W. Holderried, Catharina van Elssen, Aristoteles Giagounidis, Marij J.P. Welters, Sjoerd H. van der Burg, Hester J.T. van Zeeburg, Jeroen Rovers, Bjorn T. Gjertsen

Blood (2022) 140 (Supplement 1): 3410–3411.

https://doi.org/10.1182/blood-2022-163116

Published: 2022

Journal Articles

Use of an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML-Patients Results in MRD Conversion, Improved Relapse-Free Survival and Vaccine Induced Immune Responses to Tumor Antigens

Arjan A. Van de Loosdrecht, Jacqueline Cloos, Eva-Maria Wagner-Drouet, Uwe Platzbecker, Tobias A.W. Holderried, Catharina van Elssen, Aristoteles Giagounidis, Sören Lehmann, Hester J.T. van Zeeburg, Jeroen Rovers, Bjorn T. Gjertsen

Blood (2022) 140 (Supplement 1): 1714–1715.

https://doi.org/10.1182/blood-2022-162169

Published: 2022

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation Achieves Long-Term Survival in Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Blood (2022) 140 (Supplement 1): 2306–2307.

https://doi.org/10.1182/blood-2022-164637

Published: 2022

Journal Articles

Standard of Care CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Does Bridging Efficacy Matter? a German GLA/DRST Real World Analysis

Blood (2021) 138 (Supplement 1): 3822.

https://doi.org/10.1182/blood-2021-146120

Published: 2021

Journal Articles

Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia

Christina Rautenberg, Friedrich Stölzel, Christoph Röllig, Matthias Stelljes, Verena I Gaidzik, Michael Lauseker, Oliver Kriege, Mareike Verbeek, Julia M. Unglaub, Felicitas Thol, Stefan W. Krause, Mathias Haenel, Charlotte Neuerburg, Vladan Vucinic, Christian Jehn, Julia Severmann, Maxi Wass, Lars Fransecky, Jens Chemnitz, Udo Holtick, Kerstin Schäfer-Eckart, Josephine Schröder, Sabrina Kraus, William Hermann Krüger, Ulrich Kaiser, Sebastian Scholl, Lea Henning, Guido Kobbe, Rainer Haas, Nael Alakel, Maximilian Alexander Röhnert, Katja Sockel, Maher Hanoun, Uwe Platzbecker, Tobias A. W. Holderried, Anke Morgner, Michael Heuser, Tim Sauer, Katharina S. Goetze, Eva Maria Wagner, Konstanze Döhner, Hartmut Döhner, Christoph Schliemann, Johannes Schetelig, Martin Bornhäuser, Ulrich Germing, Thomas Schroeder, Moritz Moritz Middeke

Blood (2021) 138 (Supplement 1): 33.

https://doi.org/10.1182/blood-2021-153440

Published: 2021

Journal Articles

Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in AML Patients Shows MRD Conversion and Improved Survival

Arjan A. Van de Loosdrecht, Jacqueline Cloos, Eva Maria Wagner, Uwe Platzbecker, Tobias A. W. Holderried, Janine van Elssen, Aristoteles Giagounidis, Soren Lehmann, Hester van Zeeburg, Jeroen Rovers, Bjorn T. Gjertsen

Blood (2021) 138 (Supplement 1): 1274.

https://doi.org/10.1182/blood-2021-148333

Published: 2021

Journal Articles

Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis

Blood (2021) 138 (Supplement 1): 1748.

https://doi.org/10.1182/blood-2021-151469

Published: 2021

Journal Articles

Donor Genetic Determinant of Thymopoiesis rs2204985 Impacts Clinical Outcome after Single HLA Mismatched HSCT

Blood (2021) 138 (Supplement 1): 3903.

https://doi.org/10.1182/blood-2021-144748

Published: 2021

Journal Articles

Conversion from MRD Positive to Negative Status in AML Patients in CR1 after Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Arjan van de Loosdrecht, MD PhD, Janine van Elssen, MDPhD, Bjørn Tore Gjertsen, Eva Maria Wagner, MD, Tobias Holderried, MD, Uwe Platzbecker, Jacqueline J Cloos, Jeroen Rovers, MD PhD

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-139266

Published: 2020

Journal Articles

Safety Analysis of Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients (pts) with Steroid-Refractory (SR) Acute Graft-Vs-Host Disease (aGVHD) in the Randomized Phase 3 REACH2 Study

Blood (2020) 136 (Supplement 1): 40–42.

https://doi.org/10.1182/blood-2020-137603

Published: 2020

Journal Articles

Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-140403

Published: 2020

Journal Articles

Addition of ATIR101, an Adjunctive Treatment Following T-Cell-Depleted Haploidentical HSCT, May Decrease Non-Relapse Mortality and May Improve Survival of Patients with Hematologic Malignancies, Irrespective of Prognostic Risk Factors

Denis Claude Roy, MD, Irwin Walker, MBBS, FRCPC, Johan A. Maertens, MD PhD, Philippe Lewalle, Eduardo Olavarria, MD PhD, Yves Beguin, MD PhD, Dominik Selleslag, MD, Eva Maria Wagner, MD, Halvard Bönig, Gerard Bos, MD PhD, Stephan Mielke, MD

Blood (2019) 134 (Supplement_1): 592.

https://doi.org/10.1182/blood-2019-128344

Published: 2019

Journal Articles

Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation with Venetoclax, Hypomethylating Agents and DLI - a Retrospective Multi Center Study

Blood (2019) 134 (Supplement_1): 4563.

https://doi.org/10.1182/blood-2019-125087

Published: 2019

NARROW

Real World Results of Brexucabtagene Autoleucel for Patients with Relapsed/Refractory Mantle Cell Lymphoma - First German/Swiss Analysis

Immune-Effector-Cell-Associated-Neurotoxicity-Syndrome (ICANS) Pathophysiology Is Mediated By Microglia TGF-β-Activated Kinase-1 Signaling

Implementation of CMV-T-Track® in Clinical Routine to Guide Management of CMV Reactivation

Comparison of Fludarabine/Melphalan (FluMel) with Fludarabine/Melphalan/BCNU or Thiotepa (FBM/FTM) in Patients with AML in First Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation - a Registry Study on Behalf of the EBMT Acute Leukemia Working Party

Itacitinib and Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravitas-309

Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation

Induction of a Systemic Immune Response during Use of an Allogenic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML Patients Correlates with Clinical Response and MRD Conversion

Use of an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML-Patients Results in MRD Conversion, Improved Relapse-Free Survival and Vaccine Induced Immune Responses to Tumor Antigens

Allogeneic Hematopoietic Stem Cell Transplantation Achieves Long-Term Survival in Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Standard of Care CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Does Bridging Efficacy Matter? a German GLA/DRST Real World Analysis

Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia

Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in AML Patients Shows MRD Conversion and Improved Survival

Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis

Donor Genetic Determinant of Thymopoiesis rs2204985 Impacts Clinical Outcome after Single HLA Mismatched HSCT

Conversion from MRD Positive to Negative Status in AML Patients in CR1 after Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Safety Analysis of Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients (pts) with Steroid-Refractory (SR) Acute Graft-Vs-Host Disease (aGVHD) in the Randomized Phase 3 REACH2 Study

Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study

Addition of ATIR101, an Adjunctive Treatment Following T-Cell-Depleted Haploidentical HSCT, May Decrease Non-Relapse Mortality and May Improve Survival of Patients with Hematologic Malignancies, Irrespective of Prognostic Risk Factors

Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation with Venetoclax, Hypomethylating Agents and DLI - a Retrospective Multi Center Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only